(MedPage Today) — FDA staff noted that the benefit-risk profile of belantamab mafodotin (Blenrep) in relapsed and refractory multiple myeloma remains murky given its checkered history in a briefing document released ahead of a meeting of the agency…
Source link : https://www.medpagetoday.com/hematologyoncology/myeloma/116511
Author :
Publish date : 2025-07-15 20:03:00
Copyright for syndicated content belongs to the linked Source.
